Evaluation of the Use of Granulocyte Colony-Stimulating Factors (G-CSFs) for Neutropenia Primary Prophylaxis in Solid Tumors at a Tertiary Care Hospital, Retrospective Study
@article{Af2017EvaluationOT, title={Evaluation of the Use of Granulocyte Colony-Stimulating Factors (G-CSFs) for Neutropenia Primary Prophylaxis in Solid Tumors at a Tertiary Care Hospital, Retrospective Study}, author={Alshehri Af and A. Alnatsheh and M. Aseeri and T. Alfayea}, journal={Journal of Pharmacovigilance}, year={2017}, volume={5}, pages={1-5} }
Objective: First, to determine the appropriate prescribing of granulocyte colony-stimulating factors (G-CSFs) for febrile neutropenia (FN) as primary prophylaxis during the first cycle of chemotherapy in breast, lung, gastric, esophageal, nasopharyngeal or colorectal cancer patients. Second, to compare the incidence of FN between patients who received G-CSF appropriately and inappropriately.
Methods: This was a retrospective cohort study conducted at the Princess Norah bint Abdulrahman Al… CONTINUE READING
Figures, Tables, and Topics from this paper
2 Citations
Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors
- Medicine
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- 2019
Prescribing Pattern of Granulocyte Colony-stimulating Factor at Tertiary Care Hospital in Riyadh: An Observational Study
- Chemistry
- 2019
- Highly Influenced
- PDF
References
SHOWING 1-10 OF 52 REFERENCES
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
- Medicine
- Supportive Care in Cancer
- 2013
- 23
- PDF
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2007
- 562
- PDF
Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice Guideline
- Medicine
- International journal of hematology-oncology and stem cell research
- 2016
- 6
Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost–benefit and quality of life analysis
- Medicine
- Supportive Care in Cancer
- 2012
- 21
Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy
- Medicine
- Supportive Care in Cancer
- 2011
- 33
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
- Medicine
- BMC Cancer
- 2011
- 164
- PDF
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
- Medicine
- Supportive Care in Cancer
- 2010
- 78
- PDF
Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2012
- 30
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 1995
- 160
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.
- Medicine
- Annals of oncology : official journal of the European Society for Medical Oncology
- 2009
- 56